AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

AstraZeneca's (AZ) $1.15 billion bet on Pearl Therapeutics may soon produce returns after lung drug Bevespi Aerosphere (glycopyrrolate+formoterol fumarate) was approved by the US Food and Drug ...